select a format

Single User License
USD 250 INR 16010
Site License
USD 500 INR 32020
Corporate User License
USD 750 INR 48030

Alternatively

Request a quote
Request a Customized research
Request for Sample Report





Recent Viewed Reports


Why Ken Reasearch?


Testimonials

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ... "Mohit Mittal, Consultant, KPMG Advisory Services"

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies.... "Mustafa Masood, Financial Analyst , Coldwell Banker Riyadh"

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"

The Report was very interesting and useful for me... "Marketing Manager, Western Union Business Solutions"


Walvax Biotechnology Co Ltd (300142)-Pharmaceuticals & Healthcare-Deals and Alliances Profile

Walvax Biotechnology Co Ltd (300142)-Pharmaceuticals & Healthcare-Deals and Alliances Profile


  • Products Id :- GDPH347602D
  • |
  • Pages: 28
  • |
  • May 2017
  • |
  • |
  Request for Sample Report

Executive Summary

Summary

Walvax Biotechnology Co Ltd (Walvax) is a biopharmaceutical company that conducts research and development services. The company develops, produces and markets bio-medical products including vaccines, blood products and others. Its products include Haemophilus influenzae vaccine for the prevention of infectious diseases such as meningitis, pneumonia, septicemia, cellulitis, arthritis and epiglottitis; Group A, C meningococcal polysaccharide vaccine for preventing diseases such as cerebrospinal meningitis and septicemia; and Group ACYW135 meningococcal polysaccharide vaccine to prevent meningococcal disease. Walvax markets its products through a distribution network in China and other counties. The company operates a research and development center in Kunming and has production units in Yunnan Yuxi and Jiangsu Taizhou. Walvax is headquartered in Kunming, China.

Walvax Biotechnology Co Ltd (300142)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

Business Description-A brief description of the company's operations.

Key Employees-A list of the key executives of the company.

Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

Key Competitors-A list of the key competitors of the company.

Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications
ankur [@] kenresearch.com
+91-9015378249
www.kenresearch.com

Table of Contents

Table of Contents 2

List of Tables 3

List of Figures 4

Walvax Biotechnology Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5

Walvax Biotechnology Co Ltd, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6

Walvax Biotechnology Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7

Walvax Biotechnology Co Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 8

Walvax Biotechnology Co Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9

Walvax Biotechnology Co Ltd, Pharmaceuticals & Healthcare, Deal Details 11

Equity Offering 11

Walvax Biotech Raises USD89 Million in Private Placement of Shares 11

Walvax Biotech Plans to Raise up to USD72.9 Million in Private Placement of Shares 12

Debt Offering 13

Walvax Biotechnology Announces Public Offering Of Notes For US$188 Million 13

Walvax Biotechnology Plans Debt Offering For US$398 Million 13

Walvax Biotechnology Announces Public Offering Of Bonds For US$158 Million 14

Acquisition 14

Walvax Biotech to Sell 85% Stake in Shandong Shijie Biological Technology for USD104.5 Million 14

Walvax Biotech to Divest Kerry and Bio-Pharma and Heyzer Run Biotech for USD82 Million 15

Walvax Biotech to Sell 46% Stake in Hebei Da'an Pharma for USD103 Million 16

Walvax Biotech Plans to Acquire 51% Stake in Chongqing times Ning for USD29 Million 16

Walvax Biotech Receives Approval to Acquire Chongqing Beining Biological Pharma for USD57 Million 17

Walvax Biotech Acquires Three Biomedical Companies 18

Walvax Biotechnology To Acquire 63.57% Stake In Genor BioPharma From Shihezi Ansheng Investment And Wison Group For US$47.5 Million 18

Walvax Biotechnology To Acquire Ningbo Biological Medicine Company For US$48.5 Million 20

Walvax Biotechnology To Acquire Putian Pharma Company For US$26.3 Million 20

Walvax Biotechnology To Acquire Shandong Biological Medicine Company For US$48.5 Million 21

Walvax Biotechnology Acquires 40.61% Stake In Shanghai Biotech Company For US$19.7 Million 21

Walvax Biotechnology To Acquire Additional 35% Stake In Hebei Da'an Pharma For US$54.6 Million 22

Yunnan Walvax Acquires 58% Stake In Shanghai Zerun Biotech For US$49 Million 23

Walvax Biotechnology Completes Acquisition Of 55% Stake In Hebei Da'an Pharma For Up To US$84 Million 24

Walvax Biotechnology Co Ltd-Key Competitors 26

Locations And Subsidiaries 27

Head Office 27

Other Locations & Subsidiaries 27

Appendix 28

Methodology 28

About GlobalData 28

Contact Us 28

Disclaimer 28

List of Figures

Walvax Biotechnology Co Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 1

Walvax Biotechnology Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 1

Walvax Biotechnology Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 1

Walvax Biotechnology Co Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 1

Walvax Biotechnology Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5

Walvax Biotechnology Co Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 6

Walvax Biotechnology Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7

Walvax Biotechnology Co Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 8

List of Tables

Walvax Biotechnology Co Ltd, Pharmaceuticals & Healthcare, Key Facts, 2015 1

Walvax Biotechnology Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5

Walvax Biotechnology Co Ltd, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6

Walvax Biotechnology Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7

Walvax Biotechnology Co Ltd, Deals By Therapy Area, 2011 to YTD 2017 8

Walvax Biotechnology Co Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9

Walvax Biotech Raises USD89 Million in Private Placement of Shares 11

Walvax Biotech Plans to Raise up to USD72.9 Million in Private Placement of Shares 12

Walvax Biotechnology Announces Public Offering Of Notes For US$188 Million 13

Walvax Biotechnology Plans Debt Offering For US$398 Million 13

Walvax Biotechnology Announces Public Offering Of Bonds For US$158 Million 14

Walvax Biotech to Sell 85% Stake in Shandong Shijie Biological Technology for USD104.5 Million 14

Walvax Biotech to Divest Kerry and Bio-Pharma and Heyzer Run Biotech for USD82 Million 15

Walvax Biotech to Sell 46% Stake in Hebei Da'an Pharma for USD103 Million 16

Walvax Biotech Plans to Acquire 51% Stake in Chongqing times Ning for USD29 Million 16

Walvax Biotech Receives Approval to Acquire Chongqing Beining Biological Pharma for USD57 Million 17

Walvax Biotech Acquires Three Biomedical Companies 18

Walvax Biotechnology To Acquire 63.57% Stake In Genor BioPharma From Shihezi Ansheng Investment And Wison Group For US$47.5 Million 18

Walvax Biotechnology To Acquire Ningbo Biological Medicine Company For US$48.5 Million 20

Walvax Biotechnology To Acquire Putian Pharma Company For US$26.3 Million 20

Walvax Biotechnology To Acquire Shandong Biological Medicine Company For US$48.5 Million 21

Walvax Biotechnology Acquires 40.61% Stake In Shanghai Biotech Company For US$19.7 Million 21

Walvax Biotechnology To Acquire Additional 35% Stake In Hebei Da'an Pharma For US$54.6 Million 22

Yunnan Walvax Acquires 58% Stake In Shanghai Zerun Biotech For US$49 Million 23

Walvax Biotechnology Completes Acquisition Of 55% Stake In Hebei Da'an Pharma For Up To US$84 Million 24

Walvax Biotechnology Co Ltd, Key Competitors 26

Walvax Biotechnology Co Ltd, Subsidiaries 27

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

Walvax Biotechnology Co Ltd, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.


Related Products in vertical
Ken Research Pvt. Ltd. 27A, Tower B-2, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India
+91 1244230204

download

Company Brochure

Engage with Us

query [@] kenresearch.com